Logo - springer
Slogan - springer

Birkhäuser - Birkhäuser BioSciences | Antirheumatic Therapy: Actions and Outcomes

Antirheumatic Therapy: Actions and Outcomes

Day, R.O., Furst, D.E., Riel, P.L.C.M. van, Bresnihan, B. (Eds.)

2005, XIII, 343p.

A product of Birkhäuser Basel
Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$199.00

(net) price for USA

ISBN 978-3-7643-7726-7

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$259.00

(net) price for USA

ISBN 978-3-7643-6595-0

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short­ term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor­ der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi­ cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long­ term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav­ elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.

Content Level » Research

Keywords » Arthritis - autoimmune disease - cell - chemistry - diseases - economics - medicinal chemistry - pharmacology - quality of life - research - rheumatism - rheumatoid arthritis - therapy - toxicity - transplantation

Related subjects » Birkhäuser BioSciences

Table of contents 

Medicinal chemistry of the disease modifying anti-rheumatic drugs.- Targeting DMARD therapy.- Pharmacoeconomic properties of disease-modifying antirheumatic drugs.- Future molecular targets.- Hydroxychloroquine.- Sulfasalazine.- Parenteral gold.- Azathioprine.- Methotrexate.- Leflunomide.- Cyclosporin.- Tetracyclines.- Systemic glucocorticoids in rheumatoid arthritis.- TNF-? inhibitors.- Anakinra in rheumatoid arthritis.- Combination therapy.- Hematopoietic stem cell transplantation for the treatment of severe autoimmune diseases.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Medicine (general).